WeLaunch AI  ×  Mike Rose — [Peptide Co.]
Scope
of Work
Full-Stack Peptide Business Build — Brand, Entity, Legal,
B2B Sales Motion, B2C E-Commerce & Revenue Engine
$15,000/mo
Monthly engagement fee
$7,500 from each partner
June 2026
Engagement start
TBC upon signing
Rev Share
10–15% net revenue share
on top of base fee
Prepared for Mike Rose  ·  May 2026  ·  Strictly Confidential
01Parties & Engagement Overview
Service ProviderWeLaunch AI  ·  aviral@welaunch.ai  ·  welaunch.ai
ClientMike Rose  ·  Founder  ·  [Peptide Co.]
Engagement TypeDone-for-you full-stack peptide business build: company formation, brand identity, legal architecture, website (B2B clinic portal + B2C research storefront), B2B clinic sales motion, B2C research e-commerce, SEO, multi-channel outreach, RevOps, affiliate network, and white-label program.
Engagement Period90-day engagement. Month 1: Foundation & Build. Month 2: Launch & Initial Outreach. Month 3: First Accounts Closed & Revenue Live.
Monthly Engagement Fee$15,000 USD/month, split 50/50 — $7,500 from WeLaunch AI and $7,500 from Mike Rose's peptide entity. Invoiced at the start of each month.
Revenue ShareLane A & C (B2B clinical + white-label): 10% net revenue share to WeLaunch AI for 24 months per customer. Lane B (research B2B + B2C): 15% net revenue share to WeLaunch AI for 24 months per customer. Equity option available: 12% common in lieu of revenue share.
Mike Rose's ObligationsManufacturer capability summary (SKU list, COAs, lead times, capacity). Confirmation on entity structure. Any existing IP, brand assets, or trademarks in flight. Access to existing distribution channels and pending deals. Approximately 4–6 hours in onboarding sessions. WeLaunch handles everything else.
Day 30
Brand + entity
live
Day 60
Both websites
live
Day 75
First B2B
accounts closed
Day 90
Revenue live
& scale review
02Scope of Work — Deliverables by Workstream
14 Workstreams  ·  Done-For-You  ·  Days 1–90
Everything WeLaunch will build, launch, and operate for the peptide business.
Mike spends 4–6 hours in onboarding sessions. WeLaunch handles every build, every outreach sequence, every report, and every growth lever — end to end.
Company Naming
& DomainsThree brand name directions developed and presented (e.g. Stratum Bio, Helix North, Tessera Peptides). Final name selected, .com acquired, plus defensive extensions (.co, .bio, common misspellings). Three-domain architecture: corporate site, Lane B research storefront, Lane A clinical portal. Trademark filing on brand and key product names within 30 days.
Entity Formation
EIN, Banking & InsuranceDelaware C-Corp formation (recommended for outside capital and eventual acquisition). EIN obtained. Operating agreement, founder split, and IP assignment documented. Mercury or Brex business banking account. High-risk merchant processor configured for Lane B e-commerce (research peptides are coded high-risk — we plan around this on day one). Product liability, E&O, and general liability insurance bound with a life-sciences carrier.
Legal DocsOutside counsel retained with peptide-industry experience. Full suite drafted: Terms of Service, Privacy Policy, Refund Policy, Research-Use Agreement (signed by every Lane B buyer), Wholesale Agreement (Lane A clinic supply), White-Label MSA (Lane C partners), Affiliate Agreement. Research-use disclaimers embedded at every checkout step. Non-negotiable — this is the wall between Mike and the FDA.
Brand Identity
& PositioningFull brand identity system: logo, color palette, typography, photography direction. Premium scientific aesthetic — closer to a biotech than a supplement brand. Two visual modes: clinical (Lane A) and research (Lane B), same parent brand with distinct sub-marks. Brand positioning statement, brand pillars, and tone-of-voice guide. Packaging direction for product boxes, labels, and branded mailers.
B2B Website
(Clinic Portal)Lane A wholesale ordering portal for licensed clinics: net-30 pricing tiers, volume pricing, COA delivery per batch, reorder flow, and account management. First 10 Lane A SKUs live at launch. Age-gated, physician-verified onboarding flow. No therapeutic claims anywhere on the clinical portal — compliance posture documented throughout.
B2C E-Commerce
(Research Peptides)Lane B direct-to-researcher storefront for research peptides. Strict research-use-only labeling, "Not for Human Consumption" at every touchpoint, age-gated checkout, Certificate of Analysis downloadable per batch. First 20 Lane B SKUs live at launch. Subscription option, multi-vial bundles, loyalty tier. Built on Shopify Plus with high-risk payment stack. No therapeutic copy anywhere on the site — compliance is the foundation, not an afterthought.
Social Media
Presence & ContentBrand social channels established: Instagram, LinkedIn, and X (Twitter). Content calendar: 3 posts/week per channel, research-use framing throughout. LinkedIn executive presence for Mike Rose. Content strategy anchored in educational, research-oriented themes — Joe Rogan / Bryan Johnson angles woven into narrative. Influencer and content creator outreach for Lane B affiliate channel. No therapeutic claims, no before/after imagery, no human-use language.
SEO OptimisationFull keyword universe across three clusters: Lane A clinical (low volume, ultra-high intent B2B decision-makers), Lane B research (mid volume, high-intent researcher traffic), and educational/authority content. 8 long-form SEO articles per month, 4 short technical pieces per week, monthly regulatory update post timed to FDA PCAC meetings. Backlink program via research partnerships and guest authorship. Target: top 5 ranking for 20+ target keywords by month 9.
ICP Mapping
& EnrichmentFull Ideal Customer Profile built across three tiers. Tier 1 (highest priority): med spas, functional medicine clinics, men's health / TRT clinics, chiropractors. Tier 2: women's health, primary care DPC, urgent care chains. Tier 3: plastic surgery, IV therapy lounges, fitness studios. Lane B additions: research labs, biotech R&D, CROs, university departments. Every tier-1 target account receives a full dossier: location count, revenue band, current peptide exposure, decision-maker mapped, and contact data verified before any outreach begins.
Multi-Channel Outreach
Email, LinkedIn & CallsProprietary WeLaunch enrichment and outreach platform deployed for this business. 2 LinkedIn accounts purchased and upgraded to Sales Navigator Advanced for prospecting. 1 primary brand domain plus 5 dedicated email campaign domains acquired. Zoho Mail configured with 2 accounts per campaign domain — 10 sending accounts total — all connected to Instantly AI. Two sending pools protect deliverability: Pool A (2 domains, 4 accounts) and Pool B (3 domains, 6 accounts). Multi-channel sequenced outreach: email, LinkedIn, and voice across 21-day cadences, personalized at the account level — not templated mass blasts. Tier-1 accounts receive cold-call outreach in addition to digital channels. Target: 40 qualified clinic conversations per month by month 3, 6–10 closed accounts by Day 90.
RevOps: Pipeline
& ReportingTriple Whale (B2C) plus custom B2B dashboards for channel attribution, CAC/LTV by cohort. Weekly pipeline report: accounts contacted, meetings booked, deals in negotiation, revenue closed. Pre-call brief for every booked demo. FedEx/UPS shipping integration so clients see real-time order status directly in their account portal.
Closing & Account
ManagementWeLaunch manages the full sales cycle from first touch to signed wholesale agreement. Discovery call, COA review, sample shipment coordination, pricing negotiation, and contract issuance. Post-close: quarterly business reviews with every Lane A account to expand SKU mix and lock in 12-month supply commitments. Churn signals monitored; reactivation sequences deployed automatically for inactive accounts.
Affiliate & Partner
NetworkThree-layer affiliate program. Clinic referral: existing Lane A clinic customers refer other clinics, earn 10–15% on first-year revenue from referred accounts. Practitioner / KOL: doctors, NPs, and integrative practitioners with audiences get a private-label storefront or affiliate code. Content creator: biohacking, longevity, and research creators get tracked links and revenue share — Lane B only, strict research-use creative compliance. Goal: 25 active affiliates by month 3.
White-Label Program
for ClinicsTurnkey white-label / private-label program: med spas, clinics, gyms, and wellness brands put their logo on Mike's supply chain. WeLaunch manages the MSA, drop-ship logistics, COA delivery, and fulfillment under Lane A or Lane B compliance posture. High-margin, sticky, and creates contracted recurring revenue — clinic networks on 12–24 month supply agreements with volume commitments. First 3 white-label deals targeted by month 3.
What Mike Does Not Need to Do
Mike does not write outreach copy, manage LinkedIn manually, build websites, draft legal documents, run SEO campaigns, or manage affiliates. The only recurring obligations are: (1) supply chain management and inventory, (2) providing product COAs and batch testing results, and (3) showing up to booked clinic demos prepared with the pre-call brief WeLaunch delivers.
All other work is done-for-you by WeLaunch AI
03Revenue Projections — Three Lanes, Conservative Assumptions
Conservative  ·  Source-Attributed  ·  Reported Weekly
Three revenue lanes compounding on one engine — conservative 90-day projections.
Three scenarios, conservative assumptions, no hockey sticks. These assume the July 2026 FDA PCAC reclassification lands modestly favorably. If reclassification opens BPC-157, TB-500, and Thymosin Alpha-1 to legal compounding, Lane A accelerates 2–3x.
$25K
Day 90
total MRR
6–10
B2B clinic accounts
closed by Day 90
25
Active affiliates
by Day 90
3
White-label deals
targeted by Day 90
Lane A — B2B Clinical
GLP-1s, TRT, HRT, and FDA-compoundable peptides supplied to licensed clinics — med spas, functional medicine, TRT, chiro. Month 3: $15K. Month 6: $60K. Month 12: $180K MRR. Average account value $3K–$8K/month recurring.
Lane B — Research
BPC-157, TB-500, CJC-1295, GHK-Cu, Ipamorelin, Semax, KPV, and the full modern peptide menu sold as research chemicals. B2B to labs and B2C e-commerce. Month 3: $10K. Month 6: $65K. Month 12: $195K MRR combined.
Lane C — White-Label
Mike's supply chain becomes the backend for clinics, gyms, and wellness brands wanting their own peptide line. Contracted 12–24 month supply agreements. Month 3: $0. Month 6: $20K. Month 12: $90K MRR. Highest margin, highest stickiness.
Regulatory Upside — July 2026 PCAC Window
The FDA Pharmacy Compounding Advisory Committee meets July 23–24, 2026 specifically to review BPC-157, KPV, TB-500, and MOTS-C for the 503A bulks list. HHS Secretary RFK Jr. has publicly signalled that approximately 14 of the 19 restricted peptides are expected to move from Category 2 back to Category 1. If even half of that reclassification lands, the legal compounding market multiplies overnight. WeLaunch will have the brand, the audience, and the distribution already built — and we open Lane A SKUs for the newly-cleared peptides on day one.
04Compliance Architecture — Three Lanes, One Company
FDA-Aware  ·  Non-Negotiable Guardrails  ·  Built-In From Day One
The wall between Mike and the FDA is not an afterthought — it is the foundation.
Most peptide businesses fail because they conflate categories or cut corners on compliance. The guardrails below are not constraints — they are what allows the business to scale without a warning letter or DOJ seizure shutting everything down at month 18.
Lane A — PermittedFDA-approved or 503A-compoundable peptides (GLP-1s, TRT, HRT) supplied exclusively to licensed clinics with medical directors and established physician-patient relationships. We do not ship these direct to consumers. The clinic prescribes; the pharmacy compounds; we supply the clinical layer.
Lane B — PermittedResearch-use-only peptides sold as research chemicals, labeled "Research Use Only — Not for Human Consumption," with full Certificates of Analysis on every batch. Buyers are research labs, biotech firms, academic institutions, and the broader research community. We never make therapeutic claims, never market for human use, never name a body system or condition anywhere in copy.
What We Will Not DoWe will not market research-use-only peptides to consumers for human use. We will not make therapeutic, weight-loss, performance, or anti-aging claims on any research SKU. We will not ship compounded GLP-1s direct to consumers. We will not source from manufacturers without verified GMP / ISO / HPLC + MS testing and current COAs. No needles sold. No bacteriostatic water sold. Research compound only.
Research Analyst
ProgrammeEvery buyer is onboarded as a "Research Analyst" — not as a retail customer. Three legal documents signed at onboarding, renewed every quarter, covering permitted use, prohibited language, and consequences for violation. Violators are locked out immediately; their recurring income is forfeited. This creates multiple contractual layers between the business and the FDA.
Platform ChoicesShopify is acceptable for Lane B if the payment stack and product descriptions are configured correctly — but we plan the high-risk merchant processor from day one rather than getting Stripe shut down at month 4. Payments for Lane B: crypto / Bitcoin option offered in addition to high-risk processor. No therapeutic claims anywhere in the checkout flow.
05Commercial Terms — Pricing, Structure & Alignment
Skin in the Game  ·  Shared Upside  ·  Transparent Economics
WeLaunch puts $7,500/month in — we only win when Mike wins.
The $7,500 WeLaunch contributes every month is real capital. The revenue share means we make serious money only if the business generates serious revenue. This is a long-term partnership, not a vendor relationship.
Monthly Fee$15,000 USD/month total. $7,500 from WeLaunch AI and $7,500 from Mike Rose's peptide entity. Invoiced at the start of each month. Payment due within 7 days of invoice.
Revenue Share —
Lane A & C10% net revenue share to WeLaunch AI on Lane A (B2B clinical) and Lane C (white-label) revenue, calculated for 24 months from each customer's first order, paid monthly. Net revenue = gross revenue minus refunds, processing fees, and direct COGS.
Revenue Share —
Lane B15% net revenue share to WeLaunch AI on Lane B (research B2B + B2C e-commerce) revenue, calculated for 24 months from each customer's first order, paid monthly.
Equity OptionAlternative to revenue share: 12% common equity in the operating entity in lieu of revenue share, reflecting the full operational lift of building the company end-to-end. Open to discussion and structuring.
Out-of-Pocket Expenses
(Not in Fee)Legal (outside counsel): est. $8K–$15K upfront, then ~$2K/month. Insurance: est. $400–$800/month. Inventory and 3PL: borne by Mike's entity. Paid media when activated: managed at 10–15% management margin on top of fee. Domain registrations: ~$200 total.
Term & Exit90-day engagement. Either party may elect not to renew at Day 90 with 30 days' written notice. Mike retains all IP produced: brand, sequences, websites, legal templates, and all built assets. WeLaunch retains rights to its underlying platform and methodology.
What's Included
in the FeeFull brand, entity, web, and infrastructure stand-up (Days 1–30). B2B sales motion: target list, enrichment, multi-channel outreach, meeting booking, deal management. B2C marketing: SEO, content, email/SMS, affiliate program management. White-label program management. Account management for Mike and review gates. All software costs absorbed by WeLaunch up to defined caps. Dedicated team: 1 GM/strategy lead, 1 SDR/BDR pod, 1 marketing/content lead, 1 ops/CSM, fractional design and engineering.
Outreach
Infrastructure2 LinkedIn accounts purchased and upgraded to Sales Navigator Advanced for prospecting and outreach. 1 primary brand domain acquired plus 5 additional domains exclusively for email campaigns. Zoho Mail configured with 2 email accounts per campaign domain — 10 sending accounts in total. All 10 accounts connected to Instantly AI for warm-up and campaign execution across two sending pools: Pool A runs on 2 domains with 4 accounts; Pool B runs on 3 domains with 6 accounts. This split-pool architecture protects deliverability and maximises campaign reach.
06Why WeLaunch AI — The Unfair Advantage
40-Person Team  ·  3.5 Years Built  ·  $50M+ Monthly GMV
We are not an agency. We are a RevOps build-and-scale partner for businesses that have a real product.
WeLaunch has been building its proprietary outreach and enrichment engine for three and a half years. The same engine that generates $50M+ in monthly GMV across cars, franchises, car washes, pest control, and B2B SaaS is now being pointed at peptides — for the first time.
Proprietary Outreach Platform
WeLaunch operates an in-house research, enrichment, and outreach platform — not a stack of third-party tools anyone could rent. ICP enrichment: every target account profiled with revenue band, location count, current peptide exposure, and verified decision-maker contact data before a single message is sent. Multi-channel sequencing across email, LinkedIn, and voice, orchestrated across 21-day cadences. Deliverability infrastructure with dedicated sending domains and warmed inboxes.
Enterprise Data Partners
WeLaunch is an enterprise partner with Bombora, 6sense, and ZoomInfo — the largest B2B intent and enrichment platforms in the world. These companies have provided APIs and beta access because WeLaunch is among the largest sales organisations operating in New York. When combined, these platforms create a signal layer that individual operators cannot replicate. This is the moat.
Ranked on ChatGPT & Perplexity
WeLaunch's pest control client generates $1M in weekly sales after WeLaunch ranked them on ChatGPT, Perplexity, and Google — targeting AI-native buyers who no longer use traditional search. The same AI-ranking playbook will be deployed for Mike's peptide brand: when a buyer asks "what's the best research peptide supplier in the US," the answer points to this brand.
Compliance-Aware Agents
The AI agents know exactly what to say and what never to say. A human sales rep can be trapped into a prohibited claim in a live conversation. An AI agent trained on the April 7, 2026 FDA memo and the full prohibited-language library cannot. This is the single biggest risk in gray-market peptide sales — and it is solved by the AI layer.
07Review Gates & Milestones
Gate 1 — Day 30Brand name finalised, domains acquired, trademark filed. Delaware C-Corp formed, EIN, banking, and insurance bound. Outside counsel retained, all legal docs drafted. Manufacturer due diligence complete. SKU rationalisation across Lane A / B / C. Brand identity finalised. Corporate site v1 live. Outreach infrastructure built: domains warming, top 500 tier-1 targets profiled. Written sign-off required.
Gate 2 — Day 60B2B clinic portal live with first 10 Lane A SKUs. B2C research storefront live with first 20 Lane B SKUs. First outreach sequences live to tier-1 accounts. First 3–5 white-label conversations initiated. Content engine publishing on cadence. First SEO results indexing. First affiliate tier launched. Monthly pipeline review call with Mike — written report delivered 48h in advance.
Gate 3 — Day 90Full 90-day performance review. Outreach scaled to 1,000+ accounts per month. First 6–10 B2B accounts closed and shipping. B2C subscription model live. First 3 white-label deals signed. 25 active affiliates onboarded. Full P&L visibility, channel performance, and expansion plan reviewed with Mike. Renewal option selected or engagement concludes — all IP transfers to Mike's entity. No penalties, no lock-in.
08What We Need From Mike to Start
Manufacturer SummarySKU list, monthly capacity per SKU, lead times, GMP / ISO / HPLC documentation, and sample COAs. Lot traceability documentation from the factory. Freedom Laboratories (Tennessee) testing results for current inventory.
Existing DistributionAny existing customers, distribution channels, or pending deals — so WeLaunch does not conflict with anything already in motion. Craigslist ad performance to date. Open Loop / Bionic Weight Loss sub-site details.
Existing IP & AssetsAny existing brand assets, trademarks, or domain names already in flight. The 5,000 magnetic boxes already ordered. Label design and barcode configuration. Packaging photography if available.
Entity PreferenceConfirmation on entity structure — Delaware C-Corp is recommended. If Mike already has a legal entity he wants to use, details for review by outside counsel.
Counter-SignatureCounter-signature on this Scope of Work or a redline with proposed changes. Once signed, WeLaunch files the entity, acquires domains, and starts the clock on day one.
09Agreement & Signatures

By signing below, both parties agree to the scope, commercial terms, and obligations set out in this Scope of Work. This document constitutes the binding agreement for the 90-day engagement between WeLaunch AI and Mike Rose's peptide entity.

The peptide market is going to look very different in 90 days than it does today. The brands that own the channel by Q4 2026 will own the next decade of this category. WeLaunch is ready to build that brand with Mike.

Payment Terms$7,500 from each party invoiced at the start of each month. Payment due within 7 days of invoice. First invoice issued upon signed SOW receipt.
ConfidentialityBoth parties agree to keep all engagement details, pricing, strategy, and client information strictly confidential. This includes WeLaunch's methodology, tooling, outreach infrastructure, and Mike's supply chain, manufacturer relationships, and customer data.
IP OwnershipAll materials produced — brand identity, legal templates, websites, outreach sequences, content, and reporting templates — are owned by Mike's entity upon full payment. WeLaunch retains rights to its underlying platform and methodology.
Governing LawThis agreement is governed by the laws of the State of New York, USA. Disputes to be resolved by mutual negotiation before any formal proceedings.
WeLaunch AI
Aviral Bhutani
Founder  ·  WeLaunch AI  ·  aviral@welaunch.ai
Date: ___________________________
Mike Rose — [Peptide Co.]
Michael Rose
Founder  ·  [Peptide Co.]
Date: ___________________________
WeLaunch AI  ·  Mike Rose [Peptide Co.] Scope of Work  ·  May 2026 Confidential